Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/425166/2010 (9.7.10) |
Publication Date | 09/07/2010 |
Content Type | News |
The European Medicines Agency (EMA), in July 2010, started a review of the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim, to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile. |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001050.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |